Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiplatform metabolomic interlaboratory study of a whole human stool candidate reference material from omnivore and vegan donors.
Cruz AK, Alves MA, Andresson T, Bayless AL, Bloodsworth KJ, Bowden JA, Bullock K, Burnet MC, Neto FC, Choy A, Clish CB, Couvillion SP, Cumeras R, Dailey L, Dallmann G, Davis WC, Deik AA, Dickens AM, Djukovic D, Dorrestein PC, Eder JG, Fiehn O, Flores R, Gika H, Hagiwara KA, Pham TH, Harynuk JJ, Aristizabal-Henao JJ, Hoyt DW, Jean-François F, Kråkström M, Kumar A, Kyle JE, Lamichhane S, Li Y, Nam SL, Mandal R, de la Mata AP, Meehan MJ, Meikopoulos T, Metz TO, Mouskeftara T, Munoz N, Gowda GAN, Orešic M, Panitchpakdi M, Pierre-Hugues S, Raftery D, Rushing B, Schock T, Seifried H, Servetas S, Shen T, Sumner S, Carrillo KST, Thibaut D, Trejo JB, Van Meulebroek L, Vanhaecke L, Virgiliou C, Weldon KC, Wishart DS, Zhang L, Zheng J, Da Silva S. Cruz AK, et al. Among authors: choy a. Metabolomics. 2024 Nov 4;20(6):125. doi: 10.1007/s11306-024-02185-0. Metabolomics. 2024. PMID: 39495321
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, McCallum Pardey TG, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM; Novavax 2019nCoV-311 Study Group. Bennett C, et al. Lancet Infect Dis. 2024 Jun;24(6):581-593. doi: 10.1016/S1473-3099(24)00077-X. Epub 2024 Mar 6. Lancet Infect Dis. 2024. PMID: 38460525 Clinical Trial.
205 results